Glucose News and Research

RSS

Verapamil shows potential for preserving beta-cell function in type 1 diabetes

New research (the Ver-A-T1D trial) presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) (Vienna, 15-19 September) shows that slow-release (SR) verapamil (360mg daily) could have a potential effect on beta-cell function in adults with newly diagnosed type 1 diabetes.

18 Sep 2025

New trial demonstrates efficacy of tirzepatide in children and adolescents with type 2 diabetes

New research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and weight loss in children and adolescents with type 2 diabetes aged 10-17 years whose diabetes and weight are inadequately controlled with an existing treatment regimen of metformin, insulin, or both.

18 Sep 2025

Daily orforglipron GLP-1 pill achieves over 11% weight loss in global obesity trial

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with obesity but no diabetes. It also improved multiple cardiometabolic markers with a safety profile similar to other GLP-1 receptor agonists.

18 Sep 2025

Evening meals hold the key to morning glucose control in prediabetes

The way glucose is regulated at night plays a key role in fasting glucose levels the next morning, when blood sugar is expected to be at its lowest.

18 Sep 2025

Mediterranean diet may protect gums by reducing severe periodontitis

This study reveals that the Mediterranean diet may protect against periodontitis, highlighting its benefits for oral health and inflammation reduction.

18 Sep 2025

Scientists unveil new obesity drug that reprograms fat and energy use

Details of a new drug that aims to treat the underlying causes of obesity are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September).

18 Sep 2025

GLP-1RAs linked to lower risk of mortality and cardiovascular events in psoriasis patients

Psoriasis patients treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) face a 78% lower risk of death and a 44% lower risk of major cardiovascular events compared to those taking other diabetes or weight-loss medications, new research has shown.

17 Sep 2025

Tai chi improves memory and sleep in older adults with type 2 diabetes

A 12-week randomized trial found that remotely delivered Tai Chi significantly enhanced cognitive performance and sleep quality in older adults with Type 2 Diabetes. These gains surpassed those from supervised fitness walking or usual care, without increasing adverse events.

17 Sep 2025

University of Maine team develops sustainable method to cut drug production costs

One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials.

17 Sep 2025

High fat diet impairs memory formation through autophagy dysfunction

Modern lifestyles and dietary changes have significantly increased the consumption of high-fat foods, contributing to a steep rise in the prevalence of obesity, diabetes, and metabolic disorders.

17 Sep 2025

New EASD guideline combines clinical standards with lived experience

The guideline was developed in line with internationally recognized standards, including the GRADE methodology and the RIGHT reporting statement, and reflects the EASD's newly established Standard Operating Procedures for guideline development.

17 Sep 2025

GLP-1 drugs found to protect against diabetic retinopathy

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss, suggests new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 September) and published in the journal Pharmaceutics.

17 Sep 2025

The mind-gut connection: How emotional eating affects GLP-1 drug success

GLP-1 receptor agonists like Ozempic can be a lifeline for people with diabetes - helping stabilize blood glucose and lose weight which contributes to diabetes complications. But not everyone benefits equally.

17 Sep 2025

Can changing food texture reduce how much we eat? Dutch study investigates

A new randomized controlled trial protocol from the Netherlands will test whether altering the texture, and thus the eating rate, of ultra-processed foods can reduce daily energy intake. The study will investigate how sensory properties, such as food hardness, affect metabolism, appetite, and microbiome composition.

16 Sep 2025

Higher-dose semaglutide helps people lose nearly 19% of body weight

The STEP UP trial reveals semaglutide 7.2 mg significantly reduces weight compared to 2.4 mg, though it raises questions about gastrointestinal side effects.

16 Sep 2025

AlphaFold3 predicts bitter taste receptor structures with greater accuracy

Receptor proteins, expressed on the cell surface or within the cell, bind to different signaling molecules, known as ligands, initiating cellular responses.

16 Sep 2025

Younger adults and men with type 2 diabetes face higher risk of sepsis

Living with type 2 diabetes (T2D) may double the risk of developing sepsis-with those aged younger than 60 years and men particularly susceptible, according to a long-term community-based study in Australia, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept).

16 Sep 2025

Daily meal timing influences longevity risk in adults, study reveals

Researchers analysing Aging Cell data from over 33,000 US adults found a U-shaped link between daily eating window length and mortality. Eating for 11–12 hours per day was tied to the lowest risk, while very short (<8h) or long (≥15h) windows raised death risk, especially in older and White participants.

15 Sep 2025

Study warns women with type 2 diabetes against using oral estrogen therapy

In women with type 2 diabetes (T2D), use of hormone replacement therapy (HRT) skin patches is not associated with a higher risk of blood clots or stroke.

15 Sep 2025

Cannabis use may quadruple the risk of developing diabetes

Cannabis use is linked to an almost quadrupling in the risk of developing diabetes, according to an analysis of real-world data from over 4 million adults, being presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD) in Vienna, Austria (15-19 Sept).

15 Sep 2025